Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-hyper-CVD with or without Blinatumomab Is Highly Effective in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage

摘要

BackgroundThe outcome of patients with relapsed-refractory (R-R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin and blinatumomab have single-agent activity in R-R ALL. Their additions to low-intensity chemotherapy may further improved outcomes in ALL in first relapse.